| [1] |
NCCN clinical practice guidelines in oncology: Breast Cancer (Version 1.2018)[EB/OL]. (2018-11-01). [2018-12-28] www.nccn.org/patients.
|
| [2] |
Huang L, Chen S, Yang WT , et al. Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy[J]. Oncotarget, 2017,8(24):39703-39710. DOI: 10.18632/oncotarget.14407.
|
| [3] |
Klein J, Tran W, Watkins E , et al. Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis[J]. BMC Cancer, 2019,19(1):306. DOI: 10.1186/s12885-019-5499-2.
|
| [4] |
Li XB, Krishnamurti U, Bhattarai S , et al. Biomarkers predicting pathological complete response to neoadjuvant chemotherapy in breast cancer[J]. Am J Clin Pathol, 2016,145(6):871-878. DOI: 10.1093/ajcp/aqw045.
|
| [5] |
Fowble BL, Einck JP, Kim DN , et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage Ⅱ-Ⅲ breast cancer[J]. Int J Radiat Oncol Biol Phys, 2012,83(2):494-503. DOI: 10.1016/j.ijrobp.2012.01.068.
|
| [6] |
Huang EH, Tucker SL, Strom EA , et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy[J]. J Clin Oncol, 2004,22(23):4691-4699. DOI: 10.1200/JCO.2004.11.129.
|
| [7] |
Overgaard M, Nielsen HM, Overgaard J . Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials[J]. Radiother Oncol, 2007,82(3):247-253. DOI: 10.1016/j.radonc.2007.02.001.
|
| [8] |
EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C , et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:meta-analysis of individual patient data for 8 135 women in 22 randomised trials[J]. Lancet, 2014,383(9935):2127-2135. DOI: 10.1016/S0140-6736(14)60488-8.
|
| [9] |
Moo TA, El-Tamer M . ASO author reflections: locoregional recu-rrence rates are low with the selective use of pMRT in patients with T1-2 tumors and one to three positive lymph nodes[J]. Ann Surg Oncol, 2018,25(Suppl 3):691-692. DOI: 10.1245/s10434-018-7010-8.
|
| [10] |
铁剑, 张丝媛 . 乳腺癌新辅助化疗后腋淋巴结1~3枚转移的患者改良根治术后放射治疗的疗效分析[J]. 中华乳腺病杂志(电子版), 2015,9(3):168-172. DOI: 10.3877/cma.j.issn.1674-0807.2015.03.003.
|
| [11] |
Barbosa C Rocha F, Falcone AB, Buzaid AC , et al. Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian society of breast surgeons 2018[J]. Breast Cancer Res Treat, 2018,172(2):265-272. DOI: 10.1007/s10549-018-4912-x.
|
| [12] |
Shim SJ, Park W, Huh SJ , et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage Ⅱ-Ⅲ breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05)[J]. Int J Radiat Oncol Biol Phys, 2014,88(1):65-72. DOI: 10.1016/j.ijrobp.2013.09.021.
|
| [13] |
Le Scodan R, Selz J, Stevens D , et al. Radiotherapy for stage Ⅱ and stage Ⅲ breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy[J]. Int J Radiat Oncol Biol Phys, 2012,82(1):e1-e7. DOI: 10.1016/j.ijrobp.2010.12.054.
|
| [14] |
Cao L, Ou D, Shen KW , et al. Outcome of postmastectomy radiotherapy after primary systemic treatment in patients with clinical T1-2N1 breast cancer[J]. Cancer Radiother, 2018,22(1):38-44. DOI: 10.1016/j.canrad.2017.07.051.
|
| [15] |
Krug D, Lederer B, Seither F , et al. Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials[J]. Ann Surg Oncol, 2019,26(12):3892-3901. DOI: 10.1245/s10434-019-07635-x.
|
| [16] |
Wang X, Xu L, Yin Z , et al. Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy[J]. Cancer Manag Res, 2018,10:4105-4112. DOI: 10.2147/CMAR.S173628.
|